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Background. Rett syndrome (RS) is the leading cause of profound mental retardation of genetic origin in girls. Since RS is
mostly caused by mutations in the MECP2 gene, transgenic animal models such as the Mecp2-deleted (‘‘Mecp2-null’’) mouse
have been employed to study neurological symptoms and brain function. However, an interdisciplinary approach drawing
from chemistry, biology and neuroscience is needed to elucidate the mechanistic links between the genotype and phenotype
of this genetic disorder. Methodology/Principal Findings. We performed, for the first time, a metabolomic study of brain
extracts from Mecp2-null mice by using high-resolution magnetic resonance spectroscopy. A large number of individual water-
soluble metabolites and phospholipids were quantified without prior selection for specific metabolic pathways. Results were
interpreted in terms of Mecp2 gene deletion, brain cell function and brain morphology. This approach provided a ‘‘metabolic
window’’ to brain characteristics in Mecp2-null mice (n=4), revealing (i) the first metabolic evidence of astrocyte involvement
in RS (decreased levels of the astrocyte marker, myo-inositol, vs. wild-type mice; p=0.034); (ii) reduced choline phospholipid
turnover in Mecp2-null vs. wild-type mice, implying a diminished potential of cells to grow, paralleled by globally reduced
brain size and perturbed osmoregulation; (iii) alterations of the platelet activating factor (PAF) cycle in Mecp2-null mouse
brains, where PAF is a bioactive lipid acting on neuronal growth, glutamate exocytosis and other processes; and (iv) changes in
glutamine/glutamate ratios (p=0.034) in Mecp2-null mouse brains potentially indicating altered neurotransmitter recycling.
Conclusions/Significance. This study establishes, for the first time, detailed metabolic fingerprints of perturbed brain
growth, osmoregulation and neurotransmission in a mouse model of Rett syndrome. Combined with morphological and
neurological findings, these results are crucial elements in providing mechanistic links between genotype and phenotype of
Rett syndrome. Ultimately, this information can be used to identify novel molecular targets for pharmacological RS treatment.
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INTRODUCTION
Rett syndrome (RS) is an X-linked neurological disorder that
almost exclusively affects the female population. RS is the leading
cause of profound mental retardation of genetic origin in girls.
First described in the 1960s by A. Rett [1], this disorder has been
recognized as a neurological syndrome in the 1980s [2], and its
genetic basis has been discovered very recently [3]. In up to 96%
of all classic cases, RS is caused by mutations or deletions in
MECP2, a gene encoding for the MECP2 (methyl cytosine
phosphate dinucleotide guanine binding) protein which acts as
a transcriptional repressor critical for normal neuronal function
[4,5].
Like other genetic disorders, RS is characterized by abnormal
expression of a gene, resulting in a clinical phenotype. Conse-
quently, research on genotype-phenotype correlation, i.e. the
association between the presence of a certain mutation (genotype)
and the resulting traits (phenotype), is crucial for establishing the
basic link between altered gene expression and the disorder.
Beyond genotype-phenotype correlation studies, the elucidation of
actual mechanisms leading from particular genetic changes to
specific symptoms is a rather challenging task. Multiple levels are
involved including gene transcription, protein expression and
posttranslational protein modification, all resulting in changes of
the complex metabolic network that determines how cells perform
specific tasks. For this reason, an interdisciplinary approach
drawing from biochemistry, molecular biology, neuroscience and
medicine is needed, with particular emphasis on the comprehen-
sive analysis of cell metabolism.
While the spectrum of postnatal neurological disorders caused
by MECP2 mutations is rather broad [5], a number of behavioral,
neuroanatomical and neurochemical features are consistently
associated with classic RS. Affected girls appear to be normal
until age 6–18 mo [4,5]. Their neurological development is then
arrested and begins regressing [6]. Symptoms include decelerating
head growth, resulting in autistic features, loss of skills such as
speech and purposeful hand use, irregular breathing patterns, and
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PLoS ONE | www.plosone.org 1 January 2007 | Issue 1 | e157in many cases seizures. Morphometric and volumetric studies of
subjects with RS showed microcephaly and size reductions of
certain brain regions [7–9]. In fact, the most recent ‘clinically
applicable diagnostic criteria in RS’ include ‘a deceleration of
head growth of two standard deviations’ as one of the consensus
criteria [10,11]. Cerebellar atrophy has been detected in adult RS
patients [12]. Histological investigations have revealed a reduction
in neuron size and in dendritic arborization [7]. Several groups
have conducted genotype-phenotype correlation studies to deter-
mine whether different types of mutations in MECP2 can account
for the variability of clinical features in RS patients. However,
these studies have yielded inconsistent results [4]. To enable more
systematic and better-controlled investigations, transgenic mouse
models have been engineered that are characterized by mutated
Mecp2 [5,13–16]. Among these, the Mecp2-null mouse model is
widely accepted [13–16]. All these models have been employed to
study neurological symptoms, respiration, synaptic transmission,
neurotransmitter receptors, neuronal architecture and morpholo-
gy, but also the involvement of astrocytes [4,5,17–19].
In a previous study, we have used the Mecp2-null mouse model
to determine the cerebral endophenotype associated with the lack
of the Mecp2 protein in brain by using in vivo magnetic resonance
imaging (MRI) and spectroscopy (MRS) [20]. Volumetric analysis
of MRI images have revealed important neuroanatomical
anomalies such as a size reduction of the whole brain and of
structures involved in cognitive and motor functions (cerebellum
and motor cortex) in Mecp2-/y vs. wild-type mice. These observa-
tions reflect in part changes detected previously in RS patients.
Several groups have used localized
1H MRS methods to measure
variations of N-acetylaspartate (NAA), choline, myo-inositol (myo-
Ins) and glutamate/glutamine levels in different brain regions of
RS patients [21–23]. Our in vivo MRS studies have yielded
neurochemical differences between wild-type and Mecp2-/y mice,
although the number of metabolites that can be quantitated in
vivo is rather limited. We now present a detailed metabolomic
study based on high-resolution
1H and
31P MRS of brain extracts.
The principal purpose of this pilot study is to provide a com-
prehensive analysis of the brain metabolic phenotype associated
with Mecp2 deletion [24], and to relate these results to morphol-
ogical and neurological characteristics. Like other ‘omics’ (e.g.
genomics, proteomics), metabolomics has the benefit of simulta-
neously providing a broad overview of molecular processes
without prior selection for specific pathways [25]. Notably, we
report the first phospholipidomic analysis of brain tissue
characterized by a mutation of MeCP2 in humans or animals.
This approach permits the detection of characteristic ‘‘finger-
prints’’ of metabolic processes. These in turn provide a sound
basis for further mechanistic studies by establishing well-founded
hypotheses. Ultimately, the detection of metabolic processes
related to RS features such as cerebral atrophy and neuronal
dysfunction should enable the identification of molecular targets
for more efficient pharmacological treatment of the disorder.
RESULTS
Significant differences between Mecp2-deficient mice and controls
were detected for a number of metabolites. While the presentation
of results given below is organized according to biochemical
categories, it should be kept in mind that most metabolites are
involved in multiple metabolic pathways and processes. Thus, the
context provided for individual metabolites should not be
considered exhaustive.
Mecp2 deletion alters the brain profile of
choline-containing phospholipids and cardiolipin
Our previous in vivo
1H MRS study revealed altered relative levels
of total choline (tCho) in Mecp2-deficient mice vs. controls [20],
where tCho represents several metabolites predominantly involved
in choline phospholipid metabolism (choline, Cho; phosphocho-
line, PC; glycerophosphocholine, GPC), plus substantial contribu-
tions from phosphoethanolamine and taurine [25]. The phospho-
diester, glycerophosphocholine, is a phospholipid (PL) degradation
product while choline and the phosphomonoester, phosphocho-
line, are both phospholipid anabolites and catabolites. Since
individual choline compounds and phospholipid classes cannot be
quantitated by in vivo MRS, we determined their (absolute) tissue
levels by
1H MRS of whole-brain extracts (Fig. 1). Each of the
three choline species mentioned above showed a trend towards
decreased levels in Mecp2-deficient mice vs. controls (Table 1); the
difference was close to statistical significance for choline (ca.
240%; p=0.077), but not for the phosphorylated choline species.
For the sum of these three choline compounds, a slight decrease
was observed (not significant), in agreement with our previous in
vivo results obtained at a short echo time [20]. Interestingly, the
PC/GPC ratio was clearly increased by 30% (p=0.034), mostly
due to a GPC decrease (Table 1).
Table 1. Metabolite levels in Mecp2-/y and control mouse brain (mmol/g wet weight, and molar ratios for selected metabolites)
..................................................................................................................................................
Cho PC GPC PC/GPC PC+GPC tCho glu gln
controls 0.1360.03 0.3960.06 0.5360.07 0.7460.03 0.9260.13 1.0560.03 5.5360.65 3.0160.26
Mecp2-/y 0.0860.02 0.3860.11 0.4160.15 0.9760.15 0.7960.25 0.8760.27 5.0060.94 4.1760.71
P 0.077 1.000 0.289 0.034* 0.480 0.480 0.480 0.034*
gln/glu Glx gly asp GABA myo-Ins tau NAA
controls 0.5560.04 8.5360.87 0.6360.16 1.4660.35 1.6760.18 3.6660.63 5.9960.93 3.8661.03
Mecp2-/y 0.8660.22 9.1761.18 0.5960.13 1.3160.29 1.4760.10 2.4660.47 5.8560.62 4.1761.09
p 0.034* 0.480 0.724 0.480 0.157 0.034* 1.000 1.000
NANA scyllo-Ins lac ala ac suc Cr
controls 0.2160.03 0.0660.02 6.9061.38 0.4160.09 0.1760.02 0.4360.07 6.3361.32
Mecp2-/y 0.1560.04 0.160.06 7.3961.65 0.3660.14 0.2160.08 0.4160.06 6.4360.87
p 0.077 0.480 0.289 0.480 0.480 0.724 0.724
The number of samples per group was n=3 or 4 for controls or Mecp2-/y mice, respectively. Statistical significance was determined by a Mann-Whitney U test (see
Materials and Methods). Asterisks indicate p,0.05 (significance). Results are expressed as mean6standard deviation.
doi:10.1371/journal.pone.0000157.t001
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PLoS ONE | www.plosone.org 2 January 2007 | Issue 1 | e15731P MRS was able to distinguish 16 phospholipid classes and
subclasses (Fig. 2), fourteen of which were successfully assigned.
The analysis of PL profiles by
31P MRS showed significant differ-
ences in PL levels between Mecp2-deficient mice and controls
solely for choline-containing PL (diacyl-phosphatidylcholine, PtdC;
alkyl-acyl-phosphatidylcholine, AAPtdC; choline plasmalogen,
PtdCplasm; lyso- phosphatidylcholine, lyso-PtdC) (Table 2; see also
Table S1 for cardiolipin, CL).
All other phospholipid classes and subclasses determined were
present at very similar levels in the brains of both animal groups
(diacyl-phosphatidylethanolamine, PtdE; alkyl-acyl-phosphatidyl-
ethanolamine, AAPtdE; ethanolamine plasmalogen, PtdEplasm;
sphingomyelin, SM; lyso-sphingomyelin, lyso-SM; phosphatidyl-
serine, PtdS; phosphatidylinositol, PI; phosphatidic acid, PtdA;
phosphatidylglycerol, PtdG). Choline plasmalogen (PtdCplasm) was
decreased in Mecp2-deficient mouse brain (Table 2); however,
PtdCplasm values may be less accurate than the other PL values
since the PtdCplasm peak areas measured may be influenced by
the presence of the large PtdC signal directly upfield from
PtdCplasm. PtdS and PtdE showed a trend towards increased values
(not significant). PLtot (total phospholipids) levels did not vary
between groups, nor did the molar ratio between choline and
ethanolamine-containing phospholipids, PC-L/PE-L (Table 2). As
a matter of fact, molar fractions of phospholipids are a direct
measure of the balance of phospholipid composition that affects
the fluidity and function of membranes (Farooqui and Horrocks
2001).
Cerebral profiles of neurotransmitters in Mecp2-null
mice
Choline, introduced above as a phospholipid metabolite, is also
involved in neurotransmitter metabolism as it is an anabolite and
catabolite of acetylcholine. Other neurotransmitters and their
metabolites are closely linked to glucose (glc) metabolism. Glutamate
(glu), generally acknowledged to be the most important transmitter
for normal brain function [26], can be produced from the citric acid
cycle following pyruvate formation from glucose. We did not detect
a significant difference in glutamate between Mecp2-deficient and
control mice based on
1H spectra of brain extracts. However, the
Figure 1. Typical high-resolution
1H NMR spectrum of the brain extract from a Mecp2-deficient mouse (water-soluble metabolites). The entire spectral
region of interest (upper left spectrum) as well as magnified subregions are shown. Creatinine (Crn) was not quantified since the weak singlet was not
sufficiently separated from other peaks forming a broad hump between 3.01 and 3.06 ppm. Abbreviations: ac, acetate; ala, alanine; asp, aspartate;
Cho, choline; Cr, creatine; GABA, c-aminobutyrate; gln, glutamine; glu, glutamate; gly, glycine; GPC, glycerophosphocholine; lac, lactate; myo-Ins,
myo-inositol; NAA, N-acetylaspartate; NANA, N-acetylneuraminate; PC, phosphocholine; scyllo-Ins, scyllo-inositol; suc, succinate; tau, taurine.
doi:10.1371/journal.pone.0000157.g001
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PLoS ONE | www.plosone.org 3 January 2007 | Issue 1 | e157presynaptic precursor of glutamate, glutamine (gln), was significantly
increased in Mecp2-deficient mice by almost 40%. The glutamine/
glutamate ratio also was significantly increased in Mecp2-deficient
mice (Table 1). Aspartate (asp) is a neurotransmitter and a glutamate
metabolite, and, like glutamate, does not differ between Mecp2-
deficient and control mice. Similarly, the inhibitory neurotransmit-
ter, c-aminobutyrate (GABA), is derived from glutamate and only
shows an insignificant decrease in Mecp2-deficient vs. control mice.
Glycine (gly), another neurotransmitter [27], shows almost identical
concentrations in both groups.
Figure 2. Typical high-resolution
31P NMR spectrum of the brain extract from a Mecp2-deficient mouse (phospholipids). The entire PL region (upper
left spectrum) as well as magnified subregions are shown. Processing parameters were varied to highlight important spectral details. Abbreviations:
AAPtdC, alkyl-acyl-phosphatidylcholine; AAPtdE, alkyl-acyl-phosphatidylethanolamine; CL, cardiolipin; PLx,y, unassigned phospholipids; PtdI,
phosphatidylinositol; PtdA, phosphatidic acid; PtdC, (diacyl)phosphatidylcholine; PtdCplasm, choline plasmalogen; PtdE, (diacyl)phosphatidylethano-
lamine; PtdEplasm, ethanolamine plasmalogen; PtdG, phosphatidylglycerol; PtdS, phosphatidylserine; SM, sphingomyelin.
doi:10.1371/journal.pone.0000157.g002
Table 2. Metabolite levels in Mecp2-/y and control mouse brain (mmol/g wet weight, and molar ratios for selected metabolites)
..................................................................................................................................................
PtdC AAPtdC PtdCplasm lyso-PtdC CL PtdE PtdEplasm AAPtdE SM
controls 17.8261.28 0.2160.01 0.5060.13 0.1360.03 0.4860.03 8.8060.52 8.6560.98 0.4060.09 2.0160.11
Mecp2-/y 21.99 a61.82 0.2460.02 0.3560.03 0.0660.04 0.6060.07 10.1660.99 9.1960.71 0.7260.50 2.4760.55
p 0.034* 0.043* 0.021* 0.043* 0.083 0.149 0.248 0.248 0.149
PC-L/PE-L PtdI PtdS PtdG PtdA lyso-SM PLx PLy PLtot
controls 1.1660.01 0.8460.07 3.8760.55 0.1060.02 0.4560.07 0.1360.03 0.9460.26 0.0560.06 49.5063.25
Mecp2-/y 1.1960.03 1.0260.18 4.7260.82 0.1260.04 0.5260.03 0.3760.42 1.1860.55 0.0560.05 53.6665.12
p 0.248 0.248 0.083 0.563 0.149 0.149 0.248 0.767 0.149
The number of samples per group was n=4. Statistical significance was determined by a Mann-Whitney U test (see Materials and Methods). Asterisks indicate p,0.05
(significance). PLx and PLy represent unidentified PL classes. Results are espressed as mean6standard deviation.
a: An outlier presenting an extremely low value has been omitted from this group. With the outlier included, p values would be at ca. 0.1; however, relative PtdC levels
(PtdC/PLtot) still show a significant difference between groups (p=0.043, Mann-Whitney U test).
doi:10.1371/journal.pone.0000157.t002
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NAA is considered a neuronal marker and has also been proposed
to act as an osmolyte [28]. NAA is involved in asp metabolism and
lipid synthesis, and was found in large quantities inmouse brain (ca.
4 mmol/g). However, no differences were detected between the two
groups (Table 1).Besides GPC and glutamine mentioned above, we
quantitated two additional compounds knownas osmolytes, taurine
(tau) and myo-Ins. This polyol that is also important in phospholipid
(phosphatidylinositol) metabolism, was decreased by one third in
Mecp2-deficient mice (p=0.034 for both significance tests,
Table 1). In contrast, there was no difference in taurine levels
between the two groups studied. Neither the NAA and ketone
body-derived metabolite, acetate (ac), nor the glycolysis products,
lactate (lac) and alanine (ala), nor citric acid cycle-derived succinate
(suc) were different for the two groups analyzed. In a previous
paper, we raised the possibility that the NAA signal measured by
in vivo MRS may overlap with an unresolved signal from
N-acetylaspartylglutamate (NAAG) [20]. The latter should be
readily detectable as a separate resonance in brain extract spectra.
Nevertheless, we did not find any peak next to NAA that would be
intense enough to explain the additional signal measured in vivo
(max. 5–6% of NAA). Therefore, the extra peak observed in vivo is,
in all likelihood, not due to NAAG. Another N-acetyl compound,
N-acetylneuraminate (NANA) or sialic acid, is moderately de-
creased in Mecp2-/y mice (near significance, p=0.077, Table 1).
NANA is synthesized from glucose and is involved in the synthesis
of gangliosides that are implicated in signal transduction in
eukaryotic cells [29]. Knockout mice lacking the major gangliosides
of brain are highly susceptible to induced seizures [30]; however,
little is known about a specific role of NANA in Rett syndrome.
DISCUSSION
A metabolic pattern that is based on a number of metabolites
implicated in a common pathway can be considered a ‘‘finger-
print’’ of the metabolic process involved. Our metabolomic analysis
revealed that the concentrations of several brain metabolites
involved in different pathways varied significantly between Mecp2-
null mice and controls. The biochemical processes include primar-
ily membrane lipid metabolism, osmoregulation and glutamatergic
neurotransmission. These will be interpreted in the context of
morphological, neurological and functional differences between
normal brains and brains characterized by Mecp2 deletion.
How are membrane phospholipids and brain (cell)
growth linked in Mecp2-/y mice?
To our knowledge, the present study contains the first detailed
quantitative analysis of membrane phospholipid classes and sub-
classes (phospholipidomics) in brain tissue with a mutated Mecp2 or
MECP2 gene. PL metabolism plays an essential role in cell growth
since PL form the matrix of cell membranes, and membrane syn-
thesis is indispensible for cell growth. In fact, brain growth defects
resulting in decreased head size and reduced neuronal cell size are
one of the hallmarks of RS [7]. Global reduction in brain size and
several of the morphological anomalies detected in RS patients
have also been observed in the Mecp2-deficient mice used in this
study [20]. Moreover, knockdown of Mecp2 levels in dissociated
embryonic non-neuronal cells from mice has been shown to
reduce their proliferation [19]. These effects point to growth
perturbation in Mecp2-deficient brain tissue, and should therefore
be reflected by parameters characterizing the biosynthesis and
degradation of cellular membranes. Nonetheless, studies of
cerebral membrane lipids in RS have been scarce, and have not
included quantitation of individual phospholipid classes [31–33].
The individual steps of PtdC synthesis and degradation are
well known (Kennedy pathway, Figure S1), and the role of PtdC
turnover in membrane production and cell growth is well
established. Therefore, the PtdC metabolite pattern observed in
Mecp2-deficient mouse brain can be interpreted in terms of
membrane PtdC turnover and cell growth, as outlined in the
legend to Figure S1. The metabolic fingerprint of a reduced PtdC
turnover rate indicates that the brain cells of Mecp2-deficient mice
possess a reduced potential to boost PtdC production when cells
are in a growing state [34,35]. This may limit the ability of cells to
grow, a mechanism potentially underlying brain growth arrest in
Mecp2-deficient mice (see scheme below).
Autopsy of both RS patients and Mecp2 mutant mice has
revealed that the brain size is reduced without reduction of the
number of neurons [36]. However, the size and dendritic arboriza-
tion of neurons are reduced. On the other hand, there are up to
ten times less neurons than glial cells (mainly astrocytes) in the
brain. Recently published evidence suggests that, in fact, suppres-
sion of astrocyte growth may contribute to microcephaly in RS
[19]. Thus, the choline PL pattern suggesting reduced growth
potential in Mecp2-deficient mouse brain may represent in part
non-neuronal cells. Indeed, reduced levels of the astrocyte marker,
myo-inositol, in the brains of Mecp2-/y mice would be consistent
with the assumption of a reduced number of astrocytes (see
discussion of osmolytes below). While the interpretation of our
PtdC data in terms of reduced cell growth is straight forward and
rather compelling, the extent to which astrocytes and neurons are
responsible for growth reduction awaits further clarification (Table
S2). Experiments on co-cultured Mecp2-/y astroglial cells and
neurons could be performed to study the relationship between
metabolism and growth in each cell type [37]. Immunohisto-
chemistry of brain tissue sections from Mecp2-/y mice may be
employed to test the hypothesis of a more pronounced growth
impairment in astrocytes vs. neurons, although correct quantita-
tion of astrocytes may be rather difficult for reasons outlined
elsewhere [38].
Potential role of PAF-remodeling in
neurotransmission of Mecp2-deficient mice
PL metabolism is not only essential to cell growth. PL remodeling
plays an important role in the generation of lipid messengers and
in intracellular signaling. The characteristic differences in choline
PL containing diacyl and acyl-alk(en)yl moieties between Mecp2-
deficient mice and controls point to modifications of the platelet
activating factor (PAF) remodeling pathway or ‘‘PAF cycle’’
(Figure S2) [39]. PAF is an acyl-alkyl PL that modulates a range of
cellular processes. PAF effects relevant to the CNS may include
enhancement of glutamate exocytosis, neuronal migration,
memory formation, and collapse of growth cones essential to the
formation of synapses (Table S2) [39]. While our results support
the hypothesis of an altered PAF cycle in the Mecp2-null mouse
brain, we have no direct evidence of changed PAF concentrations
since PAF levels are below the detection threshold of our MRS
experiments. Highly sensitive techniques such as mass spectrom-
etry should be employed to reveal whether the levels of PAF (and
a number of PAF metabolites) are indeed modified as a result of
the perturbations detected in this report. This would be of
particular interest considering that PAF is known to activate
excitatory synapses by increasing presynaptic glutamate release.
Future studies have to determine if PAF plays a role in RS.
Rett Syndrome Brain Metabolism
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glutamate metabolism
Altered glutamine/glutamate ratios found in the Mecp2-null mouse
brain may be explained based on previously published evidence of
heightened excitatory activity in girls with RS [40]. The latter
finding indicates that glutamate production and release from
neurons are enhanced, while normal postsynaptic signal trans-
duction may be disrupted due to overexcitation by increased gluta-
mate release. Perturbed signaling and/or dysregulation mediated
by astrocyte-associated glutamate receptors [41] may trigger
increased glutamate uptake and glutamate-glutamine conversion
in astrocytes, increasing glutamate-glutamine cycling (Figure S3).
This would be consistent with (i) data showing an increase in
metabolic activity in glia upon increased glutamate release from
neurons [42], and (ii) previously reported reduction of brain ATP
levels in Mecp2-null mice [20] since ATP is also consumed in the
synthesis of glutamine from glutamate [43]. Glutamate levels may
be kept constant by compensatory glutamate synthesis from glucose
and by anaplerosis (Table S2) [44,45]. In fact, the glutamate-
glutamine cycle and neuronal activity are tightly linked to glucose
metabolism (Figure S3), and elevated glutamate concentrations
found in the CSF of RS patients have also been interpreted in
terms of enhanced glucose utilization [22].
An alternative explanation for increased glutamine levels in
Mecp2-null mice may be a reduction in glutaminase activity, caused
by a decreased need for glutamate neurotransmitter production
due to a reduced number of synapses [17]. The latter might be
a consequence of reduced dendritic arborization [40]. Also in this
model, compensatory glutamate synthesis may maintain stable
glutamate levels as suggested above. While a perturbation of the
glutamate-glutamine cycle in the Mecp2-null mouse brain is well
supported by our data, mechanistic details remain to be elucidated.
A quantitative investigation of the relationship between glutamate-
glutamine cycling, glucose and energy metabolism in RS would
have to include flux measurements based on
13C-labeled glucose
as a precursor, and would also have to consider a possible role of
GABA [46].
Osmoregulation is perturbed in Mecp2-deficient
mice
Myo-inositol levels were markedly decreased in Mecp2-deficient
mice vs. controls, in both in vivo [20] and in vitro MRS measure-
ments. Among all the water-soluble compounds quantitated in this
study, the myo-inositol decrease and glutamine increase occurred
with the highest statistical significance. In addition, the levels of
both compounds were negatively correlated for all samples
combined (p=0.05, Spearman-Rank test), and myo-inositol was
decreased by about the same amount (1.21 mmol/g tissue wet
weight) as glutamine was increased (1.16 mmol/g). Since both
compounds exert an osmoregulatory function, one may speculate
that the increased glutamine accumulation discussed above may
have triggered a compensatory decrease in myo-inositol. Such an
effect has been described for cultured astrocytes [45], and may also
occur when intracellular glutamine concentration is increased due
to other mechanisms caused by Mecp2-deletion. Since myo-inositol
is considered to be an astrocyte marker, a decreased myo-inositol
level in Mecp2-deficient mice may alternatively indicate a lower
number of astrocytes rather than a compensation for glutamine
increase (see above and Table S2). However, a drastic reduction of
the number of astrocytes vs. neurons is unlikely because in this
case, a significant decrease in creatine would have been observed
for Mecp2-deficient mice as creatine is more expressed in
astrocytes than in neurons [47]. Further studies are necessary to
clarify this point, as suggested above in the discussion of PL
metabolism and cell growth. Future studies with alternative Mecp2
mutations (nonsense/missense, overexpression) should reveal
whether the observed myo-inositol effect is specific to the particular
animal model employed [20]. Reduced myo-inositol levels have not
been reported in the brains of RS patients to date; however, only
a few case reports are available on subjects with variable age, while
brain myo-inositol concentrations are known to change with age
even in healthy children [48].
Conclusion
The quantitative analysis of a large number of brain metabolites
allowed us to obtain, for the first time, a comprehensive
characterization of the metabolic phenotype associated with Mecp2
mutation. Most importantly, metabolic fingerprints of reduced
choline phospholipid turnover were detected, implying diminished
cell growth in agreement with reduced brain size (see also Table
S2). Moreover, indicators of altered osmoregulation in Mecp2-null
mouse brain suggest another link to changes in brain size,
potentially caused by neurons and astrocytes. In addition, changed
neurotransmitter metabolism hints at specific mechanisms of brain
dysfunction due to Mecp2 deletion. These hypotheses open new
avenues for studying the genotype-phenotype correlation in RS,
and for the identification of novel molecular targets for more
efficient pharmacological RS treatment. They also serve as a basis
for future studies investigating brain metabolism across the age
spectrum of the animals, including measurements at a presymp-
tomatic stage with the potential to distinguish between primary
and secondary effects of Mecp2 deletion.
MATERIALS AND METHODS
Animals
Experiments were performed using the mouse model strain
B6.129P2(C)-Mecp2
tm1-1Bird as described previously [20]. Briefly,
the mice obtained from Jackson Laboratory were maintained on
a C57BL/6 background. Hemizygous mutant males were
generated by crossing heterozygous knockout females to
C57BL/6 males. All experiments were performed in hemizygous
Mecp2-deficient males of 5–8 weeks of age. Although RS in
humans predominantly affects female patients, most researchers
use Mecp2-/y male mice for their studies. This choice is dictated
by the fact that the Mecp2 gene is X-linked in mouse and in
humans, and females will thus have a different amount of normally
Mecp2-expressing cells depending on their X-chromosome in-
activation profile. Since the proportion of Mecp2-deleted X
chromosomes that will be inactivated in a given female animal is
unpredictable, we decided to use Mecp2-/y male mice that
correspond to a complete absence of the Mecp2 gene product in
all cells (i.e., a real null phenotype) [20]. One consequence of
complete Mecp2 suppression is that these animals are extremely
frail, and therefore are difficult to reproduce in large numbers.
Hence, while Mecp2-/y males are a widely accepted RS model, it is
not an ideal model. Interestingly, a recent publication comparing
a male and a female RS model demonstrated that both models
exhibited very similar somatic growth and behavioral changes
[49]. In this pilot study, four Mecp2-/y mice and four C57BL/6
controls were used. The experimental procedures were carried out
in keeping with the European Guidelines for the Care and Use of
Laboratory Animals (Council Directive 86/6009/EEC).
Sample preparation
Animals were sacrificed by cervical dislocation. The brain was
swiftly and entirely removed through an incision in the skull,
Rett Syndrome Brain Metabolism
PLoS ONE | www.plosone.org 6 January 2007 | Issue 1 | e157freeze-clamped, weighed, and stored at 280uC until extraction
with methanol/chloroform/water (4:4:4 ml). The frozen brain was
broken up into several pieces in a mortar under liquid nitrogen.
The brain pieces obtained were consecutively added to 4 ml ice-
cold methanol and immediately homogenized using a Polytron
tissue homogenizer (Kinematica, Kriens-Lucerne, Switzerland).
The sample was incubated on ice for 15 min, then 4 ml of ice-cold
CHCl3 and 4 ml 4uC water were added sequentially, under
vigorous shaking after each addition. Samples were thoroughly
vortexed and placed at 220uC overnight for phase separation.
Subsequent centrifugation at 11,000 rpm (ca. 13,000 g at max.
radius) in a Sorvall Evolution RC centrifuge (Thermo Electron
Corporation, Waltham, MA, USA) for 40 min at 4uC completed
the phase separation.
Solvents were evaporated from the chloroform/methanol phase
under a nitrogen stream, and methanol was removed from the
water/methanol phase by bubbling nitrogen through the solution
while samples were kept on ice. The aqueous solution was
lyophilized overnight, and both lyophilizate and lipid samples were
stored at 280uC. For NMR spectroscopy, lipids were dissolved in
a
2H-chloroform/methanol/water solution as described elsewhere
[50]. The lyophilizate was redissolved in D2O, and pH was
adjusted to ca. 7.0. The sample was placed in a 5-mm Wilmad
NMR tube (528-PP; Carlo Erba-SDS, Val de Reuil, France)
containing a stem coaxial insert (2 mm O.D.) filled with a D2O
solution (pH 7.7) of 20 mM sodium 3-(trimethylsilyl)-2,29,3,39-
tetradeuteropropionate (TSP-d4) for
1H MRS, and 20 mM
methylenediphosphonate (MDP) for
31P MRS, for chemical-shift
referencing and quantitation. Chemicals were purchased from
Sigma-Aldrich (Saint Quentin, Fallavier, France), except for
a number of phospholipids used for MRS signal assignment
(Doosan Serdary Research, Toronto, ON, CA).
NMR spectroscopy
1H and
31P NMR spectra at 400.1 and 162.0 MHz, respectively,
were obtained on a 9.4 T AVANCE 400 WB FT-NMR
spectrometer from Bruker (Wissembourg, France), and analyzed
with Bruker’s Topspin software (for more technical details see Text
S1). Metabolite concentrations are given as mmol/g brain tissue
(wet weight). In addition, ratios of metabolite levels are presented
where appropriate.
Statistics
The statistical methods used to detect significant differences and
correlations between groups included nonparametric tests (Stat-
view 5.0.1, Cary, NC, USA). Parametric tests such as analysis of
variance are appropriate only where the conditions of equal
variances and normal distribution are met. However, Statview’s F-
test procedure yielded unequal variances for several metabolite
concentrations and metabolite ratios, and common tests for
normal distribution do not give meaningful results when applied to
small sample groups [51,52]. Consequently, we consistently used
the nonparametric Mann-Whitney U test to determine the signi-
ficance of differences between two groups, and the nonparametric
Spearman-Rank test for correlations between metabolite levels (for
further statistical details see Table S1).
SUPPORTING INFORMATION
Text S1 Technical details and parameters for NMR spectrum
acquisition and evaluation
Found at: doi:10.1371/journal.pone.0000157.s002 (0.03 MB
DOC)
Table S1 Comparison of statistical results from parametric vs.
nonparametric tests
Found at: doi:10.1371/journal.pone.0000157.s003 (0.04 MB
DOC)
Table S2 Pathways and potential biochemical/biological effects
associated with metabolites measured in brains of Mecp2-/y and
control mice.
Found at: doi:10.1371/journal.pone.0000157.s004 (0.02 MB
DOC)
Figure S1 The Kennedy pathway of phosphatidylcholine syn-
thesis and degradation. Levels of metabolites that were signifi-
cantly increased (decreased) in the brains of Mecp2-deficient mice
vs. controls are indicated by upward (downward) arrows (no
difference was detected for underlined metabolites). Cells regulate
membrane PtdC turnover by coordinating the opposing actions of
PtdC synthesis (center) and PtdC degradation (left) [35]. In this
way, resting cells (that constitute the majority of adult brain cells)
rapidly synthesize and degrade PtdC, maintaining a constant PtdC
mass [35]. During this stationary PtdC turnover that requires
efficient PtdC degradation, cells tend to sustain relatively high
levels of the PtdC degradation product, GPC, with PC/GPC
ratios being relatively low [34,53]. Thus, the combination of high
PtdC levels and PC/GPC ratios indicates low PtdC turnover, in
agreement with an established model described elsewhere (refs. 32,
33, 50, 51). This link between PL profiles and PL turnover allows
the detection of changes in PL turnover in the absence of direct
turnover rate measurements [34,35,53,54]. High PtdC turnover
rates in the resting state allow cells to efficiently switch to PtdC
accumulation for membranesynthesis when in a growing state (e.g.
as soon as they reach the S phase), simply by blocking PtdC
degradation [35]. Several lines of evidence indicate that this
mechanism is crucial to normal cell proliferation [54]. In light of
this model, increased PtdC accumulation in the Mecp2-null mouse
brain, in conjunction with decreased levels of the PtdC degrada-
tion product, lyso-PtdC, as well as increased PC/GPC ratios,
indicates a reduced ability to degrade PtdC, resulting in restricted
PtdC production in cells when in a growing state [35].
Found at: doi:10.1371/journal.pone.0000157.s005 (2.25 MB TIF)
Figure S2 The PAF cycle (adapted from [37]). Levels of meta-
bolites that were increased (decreased) in the brains of Mecp2-
deficient mice vs. controls are indicated by upward (downward)
arrows. The concentration of underlined metabolites did not vary
between the two groups. The first step in PAF generation is the
formation of lyso-PAF from AAPtdC (I). AAPtdC can then be
resynthesized from lyso-PAF, potentially via lyso-PtdC (II).
Subsequently, lyso-PAF needs to be regenerated either by
phospholipolysis (III), or by forming PtdEplasm from AAPtdC
(IV). AAPtdC levels were significantly increased in the brains of
Mecp2-deficient mice vs. controls, indicating reduced AAPtdC
degradation and/or enhanced AAPtdC resynthesis from lyso-PAF
[52]. Of these two mechanisms, a decrease in AAPtdC degrada-
tion is more likely, given that also PtdC accumulated due to
decreased degradation (see discussion of PL turnover above and
Figure S1). The second step in PAF formation is the acetylation of
lyso-PAF (V), with an alternative route being de novo synthesis
(VI) in analogy to the Kennedy pathway for PtdC (Figure S1). In
de novo synthesis (VI), choline is phosphorylated and PC is
transferred via CDP-choline to alkyl-acetylglycerol. Finally, the
cycle is completed by the degradation of PAF to lyso-PAF (VII).
Overall, our results are consistent with an altered PAF remodeling
pathway in Mecp2-deficient brain, where AAPtdC accumulates
while de novo PAF formation may be increased. Further experi-
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indeed changed.
Found at: doi:10.1371/journal.pone.0000157.s006 (0.07 MB TIF)
Figure S3 The glutamate-glutamine cycle. The excitatory
neurotransmitter, glu, is synthesized in neurons from glutamine
by way of glutaminase (E.C. 3.5.1.2) activity. After being released
from neurons, glutamate is removed by glial Excitatory Amino
Acid Transporters (EAAT) that are increased in younger RS girls
(thick arrow), and is taken up by astrocytes together with sodium
through an energy-dependent pump. Since an increase in
intracellular Na
+ by cotransport with glutamate stimulates Na,K-
ATPase, oxygen consumption, and glucose utilization in astro-
cytes, glutamate release from neurons causes an increase in
metabolic activity in the surrounding glia [42]. Elevated glutamine
levels (arrow) and glutamine/glutamate ratios in the brains of
Mecp2-deficient mice compared to controls, at insignificant
glutamate changes (underlined), are potentially due to enhanced
conversion of glutamate to glutamine by glutamine synthetase
(E.C. 6.3.1.2) in astrocytes, accompanied by increased glutamate
synthesis via the citric acid cycle (thick arrows).
Found at: doi:10.1371/journal.pone.0000157.s001 (2.25 MB TIF)
ACKNOWLEDGMENTS
Author Contributions
Conceived and designed the experiments: NL AV PC. Performed the
experiments: NL VS. Analyzed the data: NL. Contributed reagents/
materials/analysis tools: LV PC. Wrote the paper: NL AV LV.
REFERENCES
1. Rett A (1966) U ¨ber ein eigenartiges hirnatrophisches Syndrom bei Hyper-
ammona ¨mie im Kindesalter. Wien Med Wochenschr 116: 723–726.
2. Hagberg B, Aicardi J, Dias K, Ramos O (1983) A progressive syndrome of
autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett’s
syndrome: report of 35 cases. Ann Neurol 14: 471–479.
3. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, et al. (1999) Rett
syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-
binding protein 2. Nat Genet 23: 185–188.
4. Shahbazian MD, Zoghbi HY (2002) Rett syndrome and MeCP2: linking
epigenetics and neuronal function. Am J Hum Genet 71: 1259–1272.
5. Zoghbi HY (2005) MeCP2 dysfunction in humans and mice. J Child Neurol 20:
736–740.
6. Hagberg B, Witt-Engerstrom I (1986) Rett syndrome: a suggested staging system
for describing impairment profile with increasing age towards adolescence.
Am J Med Genet Suppl 1: 47–59.
7. Armstrong DD (2001) Rett syndrome neuropathology review 2000. Brain Dev
23 Suppl 1: S72–76.
8. Reiss AL, Faruque F, Naidu S, Abrams M, Beaty T, et al. (1993) Neuroanatomy
of Rett syndrome: a volumetric imaging study. Ann Neurol 34: 227–234.
9. Subramaniam B, Naidu S, Reiss AL (1997) Neuroanatomy in Rett syndrome:
cerebral cortex and posterior fossa. Neurology 48: 399–407.
10. Hagberg B, Hanefeld F, Percy A, Skjeldal O (2002) An update on clinically
applicable diagnostic criteria in Rett syndrome. Comments to Rett Syndrome
Clinical Criteria Consensus Panel Satellite to European Paediatric Neurology
Society Meeting, Baden Baden, Germany, 11 September 2001. Eur J Paediatr
Neurol 6: 293–297.
11. Hagberg G, Stenbom Y, Witt Engerstrom I (2000) Head growth in Rett
syndrome. Acta Paediatr 89: 198–202.
12. Gotoh H, Suzuki I, Maruki K, Mitomo M, Hirasawa K, et al. (2001) Magnetic
resonance imaging and clinical findings examined in adulthood-studies on three
adults with Rett syndrome. Brain Dev 23 Suppl 1: S118–121.
13. Dani VS, Chang Q, Maffei A, Turrigiano GG, Jaenisch R, et al. (2005) Reduced
cortical activity due to a shift in the balance between excitation and inhibition in
a mouse model of Rett syndrome. Proc Natl Acad Sci U S A 102: 12560–12565.
14. Guy J, Hendrich B, Holmes M, Martin JE, Bird A (2001) A mouse Mecp2-null
mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet
27: 322–326.
15. Horike S, Cai S, Miyano M, Cheng JF, Kohwi-Shigematsu T (2005) Loss of
silent-chromatin looping and impaired imprinting of DLX5 in Rett syndrome.
Nat Genet 37: 31–40.
16. Nuber UA, Kriaucionis S, Roloff TC, Guy J, Selfridge J, et al. (2005) Up-
regulation of glucocorticoid-regulated genes in a mouse model of Rett syndrome.
Hum Mol Genet 14: 2247–2256.
17. Nelson ED, Kavalali ET, Monteggia LM (2006) MeCP2-dependent transcrip-
tional repression regulates excitatory neurotransmission. Curr Biol 16: 710–716.
18. Viemari JC, Roux JC, Tryba AK, Saywell V, Burnet H, et al. (2005) Mecp2
deficiency disrupts norepinephrine and respiratory systems in mice. J Neurosci
25: 11521–11530.
19. Nagai K, Miyake K, Kubota T (2005) A transcriptional repressor MeCP2
causing Rett syndrome is expressed in embryonic non-neuronal cells and
controls their growth. Brain Res Dev Brain Res 157: 103–106.
20. Saywell V, Viola A, Confort-Gouny S, Le Fur Y, Villard L, et al. (2006) Brain
magnetic resonance study of Mecp2 deletion effects on anatomy and
metabolism. Biochem Biophys Res Commun 340: 776–783.
21. Gokcay A, Kitis O, Ekmekci O, Karasoy H, Sener RN (2002) Proton MR
spectroscopy in Rett syndrome. Comput Med Imaging Graph 26: 271–275.
22. Naidu S, Kaufmann WE, Abrams MT, Pearlson GD, Lanham DC, et al. (2001)
Neuroimaging studies in Rett syndrome. Brain Dev 23 Suppl 1: S62–71.
23. Pan JW, Lane JB, Hetherington H, Percy AK (1999) Rett syndrome: 1H
spectroscopic imaging at 4.1 Tesla. J Child Neurol 14: 524–528.
24. Ham AL, Kumar A, Deeter R, Schanen NC (2005) Does genotype predict
phenotype in Rett syndrome? J Child Neurol 20: 768–778.
25. Lutz NW (2005) From metabolic to metabolomic NMR spectroscopy of
apoptotic cells. Metabolomics 1: 251–268.
26. Purves D, Augustine GJ, Fitzpatrick D, Hall WC, Lamantia AS, et al. (2001)
Neuroscience. 2nd ed. ed: Sinauer Associates.
27. Viola A, Chabrol B, Nicoli F, Confort-Gouny S, Viout P, et al. (2002) Magnetic
resonance spectroscopy study of glycine pathways in nonketotic hyperglycine-
mia. Pediatr Res 52: 292–300.
28. Baslow MH (2002) Evidence supporting a role for N-acetyl-L-aspartate as
a molecular water pump in myelinated neurons in the central nervous system.
An analytical review. Neurochem Int 40: 295–300.
29. Macala LJ, Yohe HC (1995) In situ accessibility of murine macrophage
gangliosides. Glycobiology 5: 67–75.
30. Wu G, Lu ZH, Wang J, Wang Y, Xie X, et al. (2005) Enhanced susceptibility to
kainate-induced seizures, neuronal apoptosis, and death in mice lacking
gangliotetraose gangliosides: protection with LIGA 20, a membrane-permeant
analog of GM1. J Neurosci 25: 11014–11022.
31. Lekman AY, Hagberg BA, Svennerholm LT (1991) Membrane cerebral lipids in
Rett syndrome. Pediatr Neurol 7: 186–190.
32. Lekman AY, Hagberg BA, Svennerholm LT (1999) Cerebrospinal fluid
gangliosides in patients with Rett syndrome and infantile neuronal ceroid
lipofuscinosis. Eur J Paediatr Neurol 3: 119–123.
33. Papadimitriou JM, Hockey A, Tan N, Masters CL (1988) Rett syndrome:
abnormal membrane-bound lamellated inclusions in neurons and oligoden-
droglia. Am J Med Genetics 29: 365–368.
34. Baburina I, Jackowski S (1999) Cellular responses to excess phospholipid. J Biol
Chem 274: 9400–9408.
35. Zhang XH, Zhao C, Seleznev K, Song K, Manfredi JJ, et al. (2006) Disruption
of G1-phase phospholipid turnover by inhibition of Ca2+-independent
phospholipase A2 induces a p53-dependent cell-cycle arrest in G1 phase. J Cell
Sci 119: 1005–1015.
36. Johnston MV, Hohmann C, Blue ME (1995) Neurobiology of Rett syndrome.
Neuropediatrics 26: 119–122.
37. Westergaard N, Fosmark H, Schousboe A (1991) Metabolism and release of
glutamate in cerebellar granule cells cocultured with astrocytes from cerebellum
or cerebral cortex. J Neurochem 56: 59–66.
38. Kimelberg HK (2004) The problem of astrocyte identity. Neurochem Int 45:
191–202.
39. Bazan NG (2003) Synaptic lipid signaling: significance of polyunsaturated fatty
acids and platelet-activating factor. J Lipid Res 44: 2221–2233.
40. Johnston MV, Jeon OH, Pevsner J, Blue ME, Naidu S (2001) Neurobiology of
Rett syndrome: a genetic disorder of synapse development. Brain Dev 23 Suppl
1: S206–213.
41. Segovia G, Del Arco A, Mora F (1999) Role of glutamate receptors and
glutamate transporters in the regulation of the glutamate-glutamine cycle in the
awake rat. Neurochem Res 24: 779–783.
42. Stanimirovic DB, Ball R, Durkin JP (1997) Stimulation of glutamate uptake and
Na,K-ATPase activity in rat astrocytes exposed to ischemia-like insults. Glia 19:
123–134.
43. Newsholme P, Procopio J, Lima MM, Pithon-Curi TC, Curi R (2003)
Glutamine and glutamate–their central role in cell metabolism and function.
Cell Biochem Funct 21: 1–9.
44. Shokati T, Zwingmann C, Leibfritz D (2005) Contribution of extracellular
glutamine as an anaplerotic substrate to neuronal metabolism: a re-evaluation by
multinuclear NMR spectroscopy in primary cultured neurons. Neurochem Res
30: 1269–1281.
Rett Syndrome Brain Metabolism
PLoS ONE | www.plosone.org 8 January 2007 | Issue 1 | e15745. Zwingmann C, Shokati T, Butterworth RF, Leibfritz D. Use of NMR
spectroscopy for the study of ammonia metabolism in astrocytes and neurons:
role of glutamine synthesis in astrocytes. Neurochem Res in press.
46. Patel AB, de Graaf RA, Mason GF, Rothman DL, Shulman RG, et al. (2005)
The contribution of GABA to glutamate/glutamine cycling and energy
metabolism in the rat cortex in vivo. Proc Natl Acad Sci U S A 102: 5588–5593.
47. Brand A, Richter-Landsberg C, Leibfritz D (1993) Multinuclear NMR studies
on the energy metabolism of glial and neuronal cells. Dev Neurosci 15: 289–298.
48. Kreis R, Ernst T, Ross BD (1993) Development of the human brain: in vivo
quantification of metabolite and water content with proton magnetic resonance
spectroscopy. Magn Reson Med 30: 424–437.
49. Picker JD, Yang R, Ricceri L, Berger-Sweeney J (2006) An altered neonatal
behavioral phenotype in Mecp2 mutant mice. Neuroreport 17: 541–544.
50. Lutz NW, Tome ME, Aiken NR, Briehl MM (2002) Changes in phosphate
metabolism in thymoma cells suggest mechanisms for resistance to dexameth-
asone-induced apoptosis. A 31P NMR spectroscopic study of cell extracts. NMR
Biomed 15: 356–366.
51. Lilliefors HW (1967) The Kolmogorov-Smirnov test for normality with mean
and variance unknown. J Amer Stat Assn 62: 399–402.
52. Sokal RR, Rohlf FJ (1995) Biometry. New York: Freeman.
53. Tome ME, Lutz NW, Briehl MM (2003) Overexpression of catalase or Bcl-2
delays or prevents alterations in phospholipid metabolism during glucocorticoid-
induced apoptosis in WEHI7.2 cells. Biochim Biophys Acta 1642: 149–162.
54. Lykidis A, Baburina I, Jackowski S (1999) Distribution of CTP:phosphocholine
cytidylyltransferase (CCT) isoforms. Identification of a new CCTbeta splice
variant. J Biol Chem 274: 26992–27001.
55. Rice SQ, Southan C, Boyd HF, Terrett JA, MacPhee CH, et al. (1998)
Expression, purification and characterization of a human serine-dependent
phospholipase A2 with high specificity for oxidized phospholipids and platelet
activating factor. Biochem J 330 (Pt 3): 1309–1315.
Rett Syndrome Brain Metabolism
PLoS ONE | www.plosone.org 9 January 2007 | Issue 1 | e157